Members |
targetComponentId |
Hodgkin's disease, lymphocytic depletion of lymph nodes of axilla and upper limb |
Hodgkin disease, lymphocytic depletion of lymph nodes of upper limb (disorder) |
Hodgkin's disease, lymphocytic depletion of lymph nodes of head, face and neck |
Hodgkin lymphoma, lymphocyte depletion of lymph nodes of head and neck (disorder) |
Hodgkin's disease, lymphocytic depletion of lymph nodes of inguinal region AND/OR lower limb |
Hodgkin disease, lymphocytic depletion of lymph nodes of lower limb (disorder) |
Hodgkin's disease, lymphocytic depletion of lymph nodes of inguinal region and lower limb |
Hodgkin disease, lymphocytic depletion of lymph nodes of lower limb (disorder) |
Hodgkin's disease, lymphocytic predominance |
Hodgkin lymphoma, lymphocyte-rich |
Hodgkin's disease, lymphocytic predominance, diffuse |
Hodgkin lymphoma, lymphocyte-rich |
Hodgkin's disease, lymphocytic-histiocytic predominance of extranodal AND/OR solid organ site |
Hodgkin lymphoma, lymphocyte-rich (disorder) |
Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of axilla AND/OR upper limb |
Hodgkin disease, lymphocytic-histiocytic predominance of lymph nodes of upper limb (disorder) |
Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of axilla and upper limb |
Hodgkin disease, lymphocytic-histiocytic predominance of lymph nodes of upper limb (disorder) |
Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of inguinal region AND/OR lower limb |
Hodgkin disease, lymphocytic-histiocytic predominance of lymph nodes of lower limb |
Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of inguinal region and lower limb |
Hodgkin disease of lymph nodes of lower limb (disorder) |
Hodgkin's disease, mixed cellularity of extranodal AND/OR solid organ site |
Hodgkin's disease, mixed cellularity (clinical) |
Hodgkin's disease, mixed cellularity of lymph nodes of axilla AND/OR upper limb |
Hodgkin disease, mixed cellularity of lymph nodes of upper limb (disorder) |
Hodgkin's disease, mixed cellularity of lymph nodes of axilla and upper limb |
Hodgkin disease, mixed cellularity of lymph nodes of upper limb (disorder) |
Hodgkin's disease, mixed cellularity of lymph nodes of inguinal region AND/OR lower limb |
Hodgkin disease, mixed cellularity of lymph nodes of lower limb (disorder) |
Hodgkin's disease, mixed cellularity of lymph nodes of inguinal region and lower limb |
Hodgkin disease, mixed cellularity of lymph nodes of lower limb (disorder) |
Hodgkin's disease, nodular sclerosis of extranodal AND/OR solid organ site |
Hodgkin's disease, nodular sclerosis (clinical) |
Hodgkin's disease, nodular sclerosis of lymph nodes of axilla AND/OR upper limb |
Hodgkin disease, nodular sclerosis of lymph nodes of upper limb |
Hodgkin's disease, nodular sclerosis of lymph nodes of axilla and upper limb |
Hodgkin disease, nodular sclerosis of lymph nodes of upper limb |
Hodgkin's disease, nodular sclerosis of lymph nodes of inguinal region AND/OR lower limb |
Hodgkin disease, nodular sclerosis of lymph nodes of lower limb (disorder) |
Hodgkin's disease, nodular sclerosis of lymph nodes of inguinal region and lower limb |
Hodgkin disease, nodular sclerosis of lymph nodes of lower limb (disorder) |
Hodgkin's disease, nodular sclerosis, mixed cellularity |
Hodgkin lymphoma, nodular sclerosis, grade 1 (morphologic abnormality) |
Hodgkin's granuloma of extranodal AND/OR solid organ site |
Hodgkin's granuloma (clinical) |
Hodgkin's granuloma of lymph nodes of axilla AND/OR upper limb |
Hodgkin granuloma of lymph nodes of upper limb (disorder) |
Hodgkin's granuloma of lymph nodes of axilla and upper limb |
Hodgkin granuloma of lymph nodes of upper limb (disorder) |
Hodgkin's granuloma of lymph nodes of inguinal region AND/OR lower limb |
Hodgkin granuloma of lymph nodes of lower limb |
Hodgkin's granuloma of lymph nodes of inguinal region and lower limb |
Hodgkin granuloma of lymph nodes of lower limb |
Hodgkin's paragranuloma |
Hodgkin lymphoma, nodular lymphocyte predominance (clinical) |
Hodgkin's paragranuloma |
Hodgkin lymphoma, nodular lymphocyte predominance |
Hodgkin's paragranuloma of extranodal AND/OR solid organ site |
Hodgkin lymphoma, nodular lymphocyte predominance (clinical) |
Hodgkin's paragranuloma of lymph nodes of axilla AND/OR upper limb |
Hodgkin paragranuloma of lymph nodes of upper limb (disorder) |
Hodgkin's paragranuloma of lymph nodes of axilla and upper limb |
Hodgkin paragranuloma of lymph nodes of upper limb (disorder) |
Hodgkin's paragranuloma of lymph nodes of inguinal region AND/OR lower limb |
Hodgkin's paragranuloma of lymph nodes of lower limb (disorder) |
Hodgkin's paragranuloma of lymph nodes of inguinal region and lower limb |
Hodgkin's paragranuloma of lymph nodes of lower limb (disorder) |
Hodgkin's sarcoma of extranodal AND/OR solid organ site |
Hodgkin's sarcoma (disorder) |
Hodgkin's sarcoma of lymph nodes of axilla AND/OR upper limb |
Hodgkin sarcoma of lymph nodes of upper limb (disorder) |
Hodgkin's sarcoma of lymph nodes of axilla and upper limb |
Hodgkin sarcoma of lymph nodes of upper limb (disorder) |
Hodgkin's sarcoma of lymph nodes of inguinal region AND/OR lower limb |
Hodgkin sarcoma of lymph nodes of lower limb (disorder) |
Hodgkin's sarcoma of lymph nodes of inguinal region and lower limb |
Hodgkin sarcoma of lymph nodes of lower limb (disorder) |
Holborn sentence reading test |
Holborn Reading Scale (assessment scale) |
Holmes Gang syndrome |
X-linked intellectual disability hypotonic face syndrome |
Homatropine hydrobromide 0.125% eye drops |
Product containing precisely homatropine hydrobromide 1.25 milligram/1 milliliter conventional release eye solution (clinical drug) |
Homatropine hydrobromide 0.25% eye drops |
Homatropine hydrobromide 2.5 mg/mL eye solution |
Homatropine hydrobromide 0.5% eye drops |
Homatropine hydrobromide 5 mg/mL eye solution |
Homatropine hydrobromide 5% eye drops |
Homatropine hydrobromide 50 mg/mL eye solution |
Homatropine hydrobromide 5%/mL solution |
Homatropine hydrobromide 50 mg/mL eye solution |
Home manager (housewife) |
Home manager |
Home nebulizer used since last appointment |
Home nebulizer used since last encounter |
Homodigital finger flap |
Flap (substance) |
Hongiella mannitolivorans |
Algoriphagus mannitolivorans (organism) |
Hordeolum internum |
Internal hordeolum (disorder) |
Hormone level in specimen from female genital organ outside reference range |
Female sex hormone outside reference range |
Hormone substitute |
Product containing hormone (product) |
Horse allergy vaccine |
Horse allergy vaccine |
Horseradish - dietary |
Horseradish (substance) |
Horseradish - dietary |
Horseradish (substance) |
Hospital physicist |
Medical physicist |
Hospital physicist |
Medical physicist |
Hot comb alopecia |
Central centrifugal cicatricial alopecia (disorder) |
environnement chaud |
Hot environment |
Hottentot |
Khoikhoi |
Hottentot language |
Khoisan language |
House dust allergy vaccine |
House dust allergy vaccine (product) |
House mite allergy vaccine |
House mite allergy vaccine (product) |
Human adenovirus 40 antigen |
Antigen of Human mastadenovirus F (substance) |
Human adenovirus 41 antigen |
Antigen of Human mastadenovirus F (substance) |
Human alpha1 proteinase inhibitor 1000mg powder for injection solution vial |
Human alpha1 proteinase inhibitor 1 g powder for solution for injection vial |
Human alpha1 proteinase inhibitor 500mg injection solution vial + diluent |
Human alpha1 proteinase inhibitor 500 mg powder for solution for injection vial |
Human alpha1 proteinase inhibitor 500mg powder for conventional release solution for injection vial |
Human alpha1 proteinase inhibitor 500 mg powder for solution for injection vial |
Human chorionic gonadotropin 10,000iu powder and solvent for injection solution vial |
Product containing precisely human chorionic gonadotropin 10000 unit/1 vial powder for conventional release solution for injection (clinical drug) |
Human coronavirus HK1 |
Human coronavirus HKU1 |
Human herpesvirus 1 group virus |
Simplexvirus |
Human herpesvirus 3 group virus |
Genus Varicellovirus (organism) |
Human immunodeficiency virus |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 1 (finding) |
Human immunodeficiency virus (HIV) infection category B1 |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 1 (finding) |
catégorie A1 d'infection au VIH des Centres for Disease Control and Prevention |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 1 (finding) |
catégorie B1 d'infection au VIH des Centres for Disease Control and Prevention |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 1 (finding) |
catégorie C1 d'infection au VIH des Centres for Disease Control and Prevention (SIDA) |
Human immunodeficiency virus Centers for Disease Control and Prevention stage 1 (finding) |
stade I d'infection au VIH selon la classification de l'Organisation mondiale de la Santé |
World Health Organization 2007 Human immunodeficiency virus infection clinical stage 1 |
stade II d'infection au VIH selon la classification de l'Organisation mondiale de la Santé |
World Health Organization 2007 Human immunodeficiency virus infection clinical stage 2 |
stade III d'infection au VIH selon la classification de l'Organisation mondiale de la Santé |
World Health Organization 2007 Human immunodeficiency virus infection clinical stage 3 (finding) |
stade IV d'infection au VIH selon la classification de l'Organisation mondiale de la Santé (SIDA) |
World Health Organization 2007 Human immunodeficiency virus infection clinical stage 4 (finding) |
classification du VIH par l'Organisation mondiale de la santé |
World Health Organization human immunodeficiency virus infection clinical stage (finding) |
séropositivité au VIH |
Human immunodeficiency virus detected (finding) |
Human immunodeficiency virus type 2 |
Human immunodeficiency virus type 2 |
Human immunodeficiency virus type I |
Human immunodeficiency virus type I |
Human immunodeficiency virus, type II glycoprotein 53 antibody |
Human immunodeficiency virus 2 protein 53 antibody (substance) |
parodontite associée au virus de l'immunodéficience humaine |
Periodontitis exacerbated by human immunodeficiency virus infection (disorder) |
Human immunoglobulin IgG 200mg/mL solution for injection |
Product containing only human immunoglobulin G (medicinal product) |
immunoglobuline humaine G à 10 %, flacon de solution injectable |
Product containing only human immunoglobulin G (medicinal product) |
immunoglobuline humaine G, flacon de 10 g d'une solution injectable |
Product containing only human immunoglobulin G (medicinal product) |
immunoglobuline humaine G, flacon de 10 g d'une poudre pour solution injectable |
Product containing only human immunoglobulin G (medicinal product) |
immunoglobuline humaine G à 16 %, flacon de solution injectable |
Product containing precisely human immunoglobulin G 160 milligram/1 milliliter conventional release solution for injection (clinical drug) |
immunoglobuline humaine G, flacon de 2,5 g d'une poudre pour solution injectable |
Product containing only human immunoglobulin G (medicinal product) |
immunoglobuline humaine G, flacon de 20 g d'une solution injectable |
Product containing only human immunoglobulin G (medicinal product) |
immunoglobuline humaine G, flacon de 5 g d'une poudre pour solution injectable |
Product containing only human immunoglobulin G (medicinal product) |
Human insulin 1mg unit dose blister dry powder for inhalation |
Human insulin-containing product |
Human insulin 3mg unit dose blister dry powder for inhalation |
Human insulin-containing product |
Human interferon gamma-1b 200 micrograms/mL injection solution 0.5mL vial |
Interferon gamma-1b 200 microgram/mL solution for injection |
Human interferon gamma-1b adverse reaction |
Adverse reaction to interferon gamma-1b |
Human leukocyte antigen A 3101 present |
Human leukocyte antigen A*31:01 detected (finding) |